Glycerol prevents loss of immunoreactive follicle-stimulating hormone and luteinizing hormone from frozen urine

1983 ◽  
Vol 98 (3) ◽  
pp. 381-384 ◽  
Author(s):  
J. H. Livesey ◽  
H. K. Roud ◽  
M. G. Metcalf ◽  
R. A. Donald
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Urine Samples ◽  
Initial Value ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

First morning urine samples were collected from both menstruant and post-menopausal women and stored at −25 °C. Immunoreactive FSH disappeared from these samples (t½ = 30 days), ultimately stabilizing at about 20% of the initial value. The loss was more rapid at −20 °C and less rapid at −55 °C and +4°C. Immunoreactive LH was also lost from frozen urine, but more slowly than FSH. The addition of glycerol to urine (0·52 mol/l) stored at −25 °C prevented loss of immunoreactive FSH and LH for at least 105 days.

The effect in post-menopausal women of natural human and artificial oestrogens on the concentration in serum of prolactin

1980 ◽  
Vol 95 (4) ◽  
pp. 433-437 ◽  
Author(s):  
Jesper Rye Andersen ◽  
Erik Schroeder ◽  
Paul Erik Lebech
Keyword(s):  
Luteinizing Hormone ◽  
Serum Concentration ◽  
Follicle Stimulating Hormone ◽  
Dose Dependence ◽  
Blood Samples ◽  
Younger Women ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Higher Doses ◽  
Stimulating Hormone

Abstract. 25 women aged 53–78 years with at least two vears menopause were divided in three groups receiving one of the following oral treatments for three weeks: 2 mg oestradiol-17β plus 1 mg oestriol, 4 mg oestradiol-17β plus 2 mg oestriol or 50 μg ethinyloestradiol daily. Blood samples were collected before, during and after the treatment and the effect on the serum concentration of prolactin, oestradiol-17β, follicle-stimulating hormone and luteinizing hormone was evaluated. During treatment with natural human oestrogens serum oestradiol-17β levels were significantly higher than before treatment. The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17β plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17β plus 2 mg oestriol or 50 μg ethinyloestradiol, thus indicating dose-dependence for natural human oestrogens. However, the increase was moderate, and these higher levels were not significantly different from levels of prolactin in serum found in 16 younger women. Concentrations of follicle-stimulating hormone and luteinizing hormon were depressed during treatment, the former to significantly lower levels when higher doses of oestrogens were used.

scholarly journals High Circulating Follicle-Stimulating Hormone Level Is a Potential Risk Factor for Renal Dysfunction in Post-Menopausal Women

2021 ◽  
Vol 12 ◽  
Author(s):  
Qihang Li ◽  
Dongmei Zheng ◽  
Haiyan Lin ◽  
Fang Zhong ◽  
Jing Liu ◽  
...  
Keyword(s):  
Renal Function ◽  
Risk Factor ◽  
Renal Dysfunction ◽  
Clinical Chemistry ◽  
Follicle Stimulating Hormone ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

ObjectiveMenopause contributes to renal dysfunction in women, which is generally attributed to estrogen withdrawal. In addition to decreased estrogen level, serum follicle-stimulating hormone (FSH) level increases after menopause. This study investigated the association between high circulating FSH level and renal function in post-menopausal women.MethodsThis observational cross-sectional study included 624 pre-menopausal, 121 peri-menopausal, and 2540 post-menopausal women. The levels of female sex hormones were examined by chemiluminescence and indices of renal function were measured using a clinical chemistry analyzer. The post-menopausal women were grouped into quartiles according to serum FSH levels.ResultsRenal function progressively declined from pre-menopause to peri-menopause to post-menopause, which was accompanied by increasing serum FSH level. In post-menopausal women, serum creatinine level increased with increasing FSH quartile, which was accompanied by a decrease in estimated glomerular filtration rate (eGFR) (p for trend <0.001); moreover, the prevalence of declined eGFR (<90 ml/min/1.73 m2) and chronic kidney disease (CKD; eGFR <60 ml/min/1.73 m2) increased (p for trend <0.001). Even after adjusting for confounders, the odds ratios (ORs) of declined eGFR and CKD increased with increasing FSH quartiles in post-menopausal women. The ORs of declined eGFR (OR=2.19, 95% confidence interval [CI]: 1.63–2.92) and CKD (OR=10.09, 95% CI: 2.28–44.65) in the highest FSH quartile were approximately 2- and 10-fold higher, respectively, than in the lowest FSH quartile (p<0.05). After stratifying post-menopausal women by median age (61 years), the OR for declined eGFR for each FSH quartile in the older group was higher than that for the corresponding FSH quartile in the younger group.ConclusionsA high circulating FSH level is an independent risk factor for renal dysfunction in women after menopause. Additionally, aging may aggravate the association of high FSH levels with reduced renal function in post-menopausal women.

scholarly journals Association of c/t polymorphism in the lrp5 gene with circulating follicle stimulating hormone in Caucasian postmenopausal women

2007 ◽  
pp. 735-739
Author(s):  
I Žofková ◽  
M Hill ◽  
K Zajíčková
Keyword(s):  
Postmenopausal Women ◽  
Sex Hormones ◽  
Restriction Analysis ◽  
Follicle Stimulating Hormone ◽  
Serum Levels ◽  
Mediating Role ◽  
Serum Lh ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

The LRP5 gene is believed to be primarily associated with bone metabolism via Wnt signaling. The latter pathway, however, appears to control various other systems outside the skeleton. To find the relationships of the LRP5 gene to serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the cohort of normal postmenopausal women, we identified the C/T (c.4037:A1330V) polymorphism in the LRP5 gene using a restriction analysis of the PCR product in a cohort of 165 untreated pre- and post-menopausal women. In a subset of 111 post-menopausal women we analyzed the association between the LRP5 genotype and serum levels of sex-hormones including FSH and LH. The distribution of CC, TC and TT genotypes of the C/T polymorphism in the whole group was 73.9 %, 23.6 % and 2.4 %, respectively, which is comparable with other Caucasian populations. As no TT homozygote was found in the group of post-menopausal women, serum sex-hormones were compared between CC and TC genotypes. Women with the CT allele combination had markedly higher serum FSH levels as compared to carriers of the CC genotype (p<0.004). No differences between these genotypes were found in serum LH levels as well as the circulating sex-steroids such as estradiol, testosterone, dehydroepiandrosterone and/or its sulphate, androstenedione and SHBG. To conclude, the LRP5 gene is associated with circulating FSH in normal post-menopausal women in the present study. The mediating role of subtle undetectable variations in estrogen levels is discussed. We did not find any relationship between the LRP-5 genotype and serum LH levels.

THE EFFECT OF CLOMIPHENE ON URINARY GONADOTROPHINS IN INFERTILE MEN

1972 ◽  
Vol 70 (4) ◽  
pp. 654-664 ◽  
Author(s):  
Peter Christiansen
Keyword(s):  
Side Effects ◽  
Luteinizing Hormone ◽  
Clomiphene Citrate ◽  
Follicle Stimulating Hormone ◽  
Urine Samples ◽  
Pronounced Increase ◽  
Infertile Men ◽  
Stimulating Hormone

ABSTRACT In order to study the effect on urinary hypophyseal gonadotrophins as measured by specific bioassays, 19 infertile men aged 26 to 47 years, average 30.8, were treated with clomiphene citrate (Clomivid®) 50 mg daily for 30 days. During the last 8 days of treatment 24 hour urine samples were collected daily for the determination of total hypophyseal gonadotrophins (HG), follicle stimulating hormone (FSH) and luteinizing hormone (LH). HG, FSH and LH rose equally to an average of 3 times the control values, the increase being highly significant statistically (P < 0.001). The most pronounced increase was observed in the cases with the lowest control values. Only one patient failed to respond. No side effects due to the drug were observed.

Sign in / Sign up

Export Citation Format

Share Document